Drug Trial Radar · NCT06163326
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
394
Actual
Start
Jan 19, 2024
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show: * if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo) * Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study * Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study. This study is seeking for participants who: * have non-segmental vitiligo (either active or stable) and * received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it. All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home. Participants may receive the study medicine or placebo for up to 52 weeks. The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo. Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study. Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.
Conditions
- Vitiligo
Interventions
RitlecitinibDrug
Ritlecitinib 50 mg capsule once daily
Ritlecitinib 100 mgDrug
Ritlecitinib 100 mg capsule once daily
PlaceboDrug
Matching capsule once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuationTime frame: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)
- Incidence of clinically significant laboratory abnormalitiesTime frame: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)
Locations
73 sites in 13 countries. Site status is shown where the registry gives one.
California Dermatology & Clinical Research Institute
Encinitas, California
Marvel Clinical Research
Huntington Beach, California
Wallace Medical Group, Inc
Los Angeles, California
Encore Medical Research of Boynton Beach
Boynton Beach, Florida
Skin Care Research
Hollywood, Florida
ForCare Clinical Research
Tampa, Florida
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
DelRicht Research
Baton Rouge, Louisiana
Lawrence J. Green, MD LLC
Rockville, Maryland
University of Michigan
Ann Arbor, Michigan
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
SUNY Downstate Health Sciences University
Brooklyn, New York
University of North Carolina Medical Center
Chapel Hill, North Carolina
Clinical & Translational Research Center (CTRC)
Chapel Hill, North Carolina
Accellacare - Wilmington
Wilmington, North Carolina
Wilmington Health, PLLC
Wilmington, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Remington-Davis, Inc
Columbus, Ohio
Medical University of South Carolina
Charleston, South Carolina
Modern Research Associates, PLLC
Dallas, Texas
Alpesh D. Desai, DO PLLC
Houston, Texas
Austin Institute for Clinical Research
Houston, Texas
The Skin Hospital
Darlinghurst, New South Wales, Australia
North Eastern Health Specialists
Campbelltown, South Australia, Australia
Skin Health Institute Inc.
Carlton, Victoria, Australia
Dr Rodney Sinclair Pty Ltd
East Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
UMHAT "Prof. Dr. Stoyan Kirkovich"AD
Stara Zagora, Bulgaria
Medical Centre "Asklepiy"
Dupnitsa, Kyustendil, Bulgaria
Diagnostic Consultative Center Aleksandrovska
Sofia, Sofia (stolitsa), Bulgaria
Centre de Recherche Dermatologique du Quebec metropolitain
Québec, Canada
Centre de Recherche Saint-Louis inc.
Québec, Canada
Dermatology Research Institute
Calgary, Alberta, Canada
CaRe Clinic
Red Deer, Alberta, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
DermEdge Research
Mississauga, Ontario, Canada
North York Research Inc
Toronto, Ontario, Canada
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
The First Hospital of Wuhan
Wuhan, Hubei, China
The First Hospital of China Medical University/Dermatology and STD Department
Shenyang, Liaoning, China
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.